公司近况2 月27 日,公司宣布自研的HER3 ADC新药AK138D1 在澳洲启动治疗晚期恶性肿瘤的I期临床,这也是公司首个进入临床的ADC药物。我们认为这是继Summit与Pfizer携手探索AK112 联用ADC后,公司在ADC领域的又一项重要进展。评论此举是康方生物推进“IO 2.0+ADC”战略的重要抓手。IO+ADC已成为IO领域的重要革命方向之一。康方生物作为全球唯一拥有两款上市IO...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.